학술논문
Association between immune-mediated adverse events (imAEs) and outcomes in metastatic urothelial cancer (mUC) treated with durvalumab (D) alone or in combination with tremelimumab (T) in the DANUBE study
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15698041